TradersLink
$NTHISep 30, 2026, 10:22 AM ETAI processed

Four biotech catalysts: NeOnc FDA meeting, Connect COPD Phase 2 win, Valion oral Entolimod, Lilly retatrutide Phase 3 weight-loss data

AI Summary

Four biotech catalysts are highlighted: NeOnc (NTHI) has an in-person End-of-Phase 1 FDA meeting set for Nov 17 for NEO212 after Phase 1 dose escalation (recommended Phase 2 dose 610 mg) and also reported supportive Phase 2a NEO100 signals; Connect Biopharma (CNTB) reported positive Phase 2 Seabreeze STAT COPD topline in 159 patients showing an 81% reduction in treatment failure through Week 4 (p=0.0122) and plans to engage the FDA on a Phase 3 registrational program. Valion Bio (VBIO) completed an oral mucosal formulation for Entolimod and now needs systemic PK/exposure data, while Eli Lilly (LLY) posted strong Phase 3 TRIUMPH-2 retatrutide results (~20% mean weight loss at 80 weeks for 12 mg and meaningful A1C reductions) and plans a BLA submission in Q1 2027.

Positives

  • CNTB Phase 2 COPD topline: 81% reduction in treatment failure through Week 4 (p=0.0122) in eosinophil-high patients
  • LLY TRIUMPH-2 retatrutide: ~20% mean weight loss at 80 weeks (12 mg) with notable A1C reductions and planned BLA in Q1 2027
  • NTHI regulatory catalyst: in-person End-of-Phase 1 FDA meeting scheduled Nov 17 after Phase 1 dose escalation (recommended Phase 2 dose 610 mg)

Negatives

  • CNTB secondary efficacy signals (FEV1 improvement) were not statistically significant (FEV1 p=0.1607) and companion asthma endpoints also missed significance
  • VBIO’s oral mucosal Entolimod still lacks human PK/systemic exposure data — efficacy and deployability remain unproven
  • Retatrutide is investigational and regulatory approval is not guaranteed despite strong Phase 3 results